Saturday 17 October 2026
Export VRAX’s income statement to Excel — free account
Virax Biolabs Group Limited
VRAX Healthcare Biotechnology
Virax Biolabs Group Limited’s revenue for fiscal 2026 (year ended March 2026) was $12,400.00, up 96.8% from fiscal 2025.
1.45
0.17
−10.49%
Follow VRAX
| Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | |
|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Piotroski F-Score |
6 | 2 | — | — | — | — | — |
P/S ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Altman Z-Score |
(5.30) | (5.04) | (5.19) | 2.33 | — | — | — |
Altman Z″-Score (non-manufacturers) |
(4.14) | (8.57) | 1.69 | 8.28 | — | (629.17) | (608.78) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Beneish M-Score |
(9.96) | — | — | — | — | — | — |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
EV/EBITDA |
0.86 | 0.56 | 0.46 | 1.23 | — | 0.00 | 0.00 |
EV/Operating CF |
0.46 | 0.26 | 0.21 | 1.22 | — | 0.00 | 0.00 |
EV/FCF |
0.42 | 0.23 | 0.20 | 1.22 | — | 0.00 | 0.00 |
Quick Ratio |
9.44 | 6.33 | 22.55 | 10.30 | 0.02 | 0.02 | 0.02 |
Current Ratio |
9.97 | 7.27 | 25.95 | 10.61 | 0.04 | 0.05 | 0.05 |
Net Debt/EBITDA |
1.08 | 0.73 | 0.56 | 1.61 | 0.01 | (0.25) | (1.41) |
Debt/Assets |
0.34% | 0.51% | 0.00% | 1.49% | 7.80% | 453.28% | 1,917.68% |
Debt/Equity |
0.00 | 0.01 | 0.00 | 0.02 | 0.00 | (0.22) | (0.91) |
Asset Turnover |
0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 3.13 | 0.00 |
Operating CF/Net income |
0.92 | 0.75 | 0.93 | 0.77 | 0.48 | 0.91 | 1.14 |
Capex/Depreciation |
(0.58) | (1.76) | (11.29) | 0.00 | — | — | — |
Interest Coverage |
(103.55) | (104.41) | (241.51) | (369.86) | (112.58) | (22.53) | (18.34) |
| (78.51%) | (114.35%) | (95.90%) | (141.62%) | 168.48% | 23.85% | 0.00% | |
| (68.11%) | (101.78%) | (88.04%) | (110.69%) | (3,870.44%) | (1,643.94%) | 0.00% | |
ROIC |
(432.65%) | (300.05%) | (262.02%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(68.70%) | (111.27%) | (131.79%) | (62.55%) | 142.79% | 78.26% | 78.26% |
Average Days of Receivables |
797.70 | 1,778.65 | 508.29 | 0.00 | — | 2.65 | 2.65 |
Research and Development Expense of Revenue |
30,148.39% | 32,242.86% | 998.72% | 25,340.70% | 0.00% | 97.09% | 70.27% |
Selling, General and Administrative Expense of Revenue |
21,525.00% | 63,371.43% | 2,937.79% | 41,303.49% | 0.00% | 415.91% | 415.91% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1,051.61% | 5,798.41% | 647.06% | 20,402.33% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Earnings Yield |
(96.91%) | (18.70%) | (29.00%) | (3.07%) | — | (0.38%) | (0.38%) |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% |
Revenue per Share |
0.03 | 0.04 | 1.95 | 0.20 | 0.00 | 12.90 | 0.11 |
Operating CF per Share |
(11.62) | (30.59) | (77.89) | (98.35) | (21.20) | (61.48) | (0.65) |
Capex per Share |
(0.64) | (4.05) | (14.52) | (4.20) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(12.27) | (34.63) | (92.41) | (102.55) | (21.20) | (61.48) | (0.65) |
Cash per Share |
16.19 | 28.34 | 44.75 | 220.06 | 0.57 | 1.83 | 0.02 |
Shareholders Equity per Share |
18.45 | 36.61 | 64.07 | 209.51 | (31.25) | (86.65) | (0.73) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
18.45 | 36.61 | 64.07 | 209.51 | (31.25) | (86.65) | (0.73) |
Free Cash Flow |
(4.88) | (5.17) | (7.41) | (4.36) | (0.81) | (0.59) | (0.74) |
Working Capital |
6.14 | 4.22 | 4.21 | 8.73 | (1.20) | (0.83) | (0.83) |
Capital Expenditures |
(0.26) | (0.60) | (1.16) | (0.18) | — | — | — |
Net Current Asset Value |
5.84 | 3.93 | 4.04 | 8.73 | (1.20) | (0.83) | (0.83) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Capex to Sales |
20.63 | 95.86 | 7.45 | 20.74 | — | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
0.38 | 0.28 | 0.11 | — | — | — | — |
Cash ROIC |
(35.34%) | (53.14%) | (84.92%) | (23.68%) | 69.34% | 92.99% | 1,358.76% |
Accounts Receivable Turnover |
0.43 | 0.05 | 1.43 | 0.00 | — | 137.56 | 0.00 |
Accounts Payable Turnover |
0.01 | 0.17 | 0.25 | 0.01 | 0.00 | 0.38 | 0.00 |
Inventory Turnover |
0.10 | 0.77 | 2.60 | 0.00 | 0.00 | 6.32 | 0.00 |
Average Days of Payables |
44,685.32 | 3,611.29 | 417.09 | 26,689.24 | 0.00 | 1,359.78 | 582.69 |
Days of Inventory on Hand |
0.00 | 581.91 | 208.37 | 0.00 | 0.00 | 57.78 | 57.78 |
Average Receivables |
0.03 | 0.12 | 0.11 | — | — | 0.00 | — |
Average Payables |
0.58 | 0.35 | 0.42 | 0.98 | 0.87 | 0.35 | — |
Average Inventory |
0.05 | 0.08 | 0.04 | — | 0.02 | 0.02 | — |
Average Assets |
7.38 | 5.96 | 7.65 | 4.93 | 0.04 | 0.04 | — |
Average Common Equity |
6.40 | 5.30 | 7.02 | 3.85 | (1.01) | (2.73) | — |
Columns are period end dates